

MPAC meeting 16-18 March 2016

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat

Ten members reported relevant interests, which are summarized below.

Of note, several members (Brian Greenwood, Marcel Tanner, Kevin Marsh, Azra Ghani, Laurence Slutsker) have been involved in RTS,S phase 3 trials, for which their interest has been assessed as significant, non-personal and specific. However, in this MPAC meeting there will be no decision point related to the RTS,S malaria vaccine and, for this reason, they will be not recused from the information session related to the topic.

Similarly, one MPAC member (Neena Valecha) whose research institution receives significant funding from insecticide and LLIN manufacturers will not be recused from Session 5 (the update from the Vector Control Advisory Group) as the session is for information only and no decision will be taken.

All reported relevant interests by MPAC members are summarized below:

Azra GHANI

Receives an academic grant funding for mathematical modelling crossing all malaria topics from multiple organizations: BMGF, MVI, MMV, Wellcome Trust, NIH. This interest was assessed to be non-personal, specific, and financially significant.*

Fred BINKA

Received research support from the Bill & Melinda Gates Foundation (BMGF) for the InDepth Network Effectiveness and Safety Studies (INESS) related to the safety and effectiveness of malaria drugs. This interest was assessed as non-personal, non-specific and not financially significant.*

Thomas BURKOT

Received consulting and research support from Intellectual Ventures for two projects on analysis in the vector control area and on the trial of a machine that would increase the specificity of any rapid diagnostic for malaria. The first concluded a year ago and the second will conclude this March 2016. This interest was assessed to be non-personal, specific, and financially significant.*

Brian GREENWOOD

Receives a research grant from PATH for the London School of Hygiene and Tropical Medicines related to the evaluation of the RTS,S vaccines in Ghana. This interest was assessed as non-personal, specific, and financially significant.*

Rose Gana Fomban LEKE

Receives research grant from the National Institute of Allergy and Infectious Diseases (NIAID), USA in malaria in pregnancy. In 2013 she chaired the Data Management and Safety Board (DMSB) for Clinical Trial on Azithromycin in pregnant women. This interest was assessed as personal, non-specific and financially significant*.

Kevin MARSH

Is on the malaria vaccines advisory group for USAID, is a principal investigator on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine trials. This interest was assessed as non-personal, specific, and not financially significant.*

Sylvia MEEK

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DFID and CDC on malaria elimination, eradication and drug resistance. This interest was assessed as being non-personal, non-specific, and financially significant.*

Marcel TANNER

Directs the Swiss Tropical and Public Health Institute, which receives research funding from Novartis Institute for Tropical Diseases, SNF, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation with regard to the RTS,S vaccine. Dr Tanner has done consulting for NITD. This interest was assessed to be non-personal, specific, and financially significant.*

Neena VALECHA

Directs the National Institute of Malaria Research – New Delhi, which receives research grant from WHOPES on large scale (Phase III) evaluation of efficacy, fabric integrity and community acceptability of Permanent 3.0 long lasting insecticide dal nets compared with Permanent 2.0 in India. And from the Vestergaard Frandsen Ltd. to evaluate the efficacy of PermaNet 3.0 long lasting insecticidal net in areas with variable dethramethirine-resistance malaria vectors in India and MMW for evaluation of pesticides. This interest was assessed as non-personal, specific and not financially significant.*

Jose Gabriel CARRASQUILLA

Directs ASIESALUD for consultancy and research in epidemiology and public health where, as principal investigator, receives a research grant from 65K to assess the impact of the introduction of Pneumo vaccine and Pertussis vaccine (in pregnant women) in South America. This interest was assessed as personal, non-specific and not financially significant.

*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1000 USD would also constitute a "significant shareholding". Last update: 10 March 2016